^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Excerpt:
Has provided a PD-L1 evaluable archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated...
Trial ID:
Source:
Title:
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.
Published date:
05/19/2021
Excerpt:
...71% had PD-L1 combined positive score (CPS) ≥1...ORR was 10% (95% CI, 2‒26); 1 patient had CR (3%), and 2 had a PR (6%). 12 patients (39%) had SD...Median PFS was 2.5 months (95% CI, 1.8‒4.2). Median OS was 5.9 months (95% CI, 2.6‒8.7)….In patients with advanced gastric cancer who received 2 prior lines of therapy, lenvatinib plus pembrolizumab demonstrated promising antitumor activity and a manageable safety profile.
DOI:
10.1200/JCO.2021.39.15_suppl.4030
Trial ID:
Source:
Title:
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort.
Published date:
01/11/2021
Excerpt:
Median PFS was 2.5 months (95% CI, 1.8−4.2). Median OS was 5.9 months (95% CI, 2.6?8.7). 28 patients (90%) had treatment-related AEs, including 13 patients (42%) with grade 35 AEs. 1 patient had a treatment-related AE that led to death (hemorrhage). 8 patients (26%) had immune-mediated AEs: hypothyroidism (n = 5), hyperthyroidism (n = 2), and pneumonitis (n = 1). There were no infusion-related reactions.In patients with advanced gastric cancer who received 2 prior lines of therapy, lenvatinib plus pembrolizumab demonstrated promising antitumor activity and a manageable safety profile...
Trial ID:
